Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries
ClinicalTrials.gov Identifier:
NCT01067521
First received: February 10, 2010
Last updated: September 9, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)